Results 11 to 20 of about 6,236 (223)

WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE [PDF]

Mediterranean Journal of Hematology and Infectious Diseases, 2018
Waldenstrom Macroglobulinemia is a rare lymphoproliferative disorder with distinctive clinical features. Diagnostic and prognostic charactrization in WM significantly changed with the discovery of two molecular markers: MYD88 and CXCR4. Mutational status
Maddalena Mazzucchelli, Anna Maria Frustaci, Marina Deodato, Roberto Cairoli, Alessandra Tedeschi   +4 more
doaj   +3 more sources

CD3xCD20 bispecific antibodies in transformed Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. [PDF]

Hemasphere
HemaSphere, Volume 10, Issue 3, March 2026.
Brocard M, Roos-Weil D, Kanagaratnam L, Hueso T, Bussot L, Papoular B, Tomowiak C, Chevreux S, Crochet G, Vaugeois T, Toussaint E, Ferrero S, Kyriakou C, Quinquenel A, Kapoor P, Durot E.   +15 more
europepmc   +2 more sources

Waldenstrom Macroglobulinemia [PDF]

Cancer Letters, 2008
In the past years, new developments have occurred both in the understanding of the biology of Waldenstrom Macroglobulinemia (WM) and in therapeutic options for WM. WM is a B-cell disorder characterized primarily by bone marrow infiltration with lymphoplasmacytic cells, along with demonstration of an IgM monoclonal gammopathy.
Xavier, Leleu, Aldo M, Roccaro, Anne-Sophie, Moreau, Sophie, Dupire, Daniela, Robu, Julie, Gay, Evdoxia, Hatjiharissi, Nicholas, Burwik, Irene M, Ghobrial   +8 more
openaire   +3 more sources

Emerging targets in human lymphoma: targeting the MYD88 mutation [PDF]

, 2016
B cell neoplasms co-opt the molecular machinery of normal B cells for their survival. Technological advances in cancer genomics has significantly contributed to uncovering the root cause of aggressive lymphomas, revealing a previously unknown link ...
Horikawa, Keisuke, Jeelall, Yogesh S., Wang, James Q.   +2 more
core   +1 more source

HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib [PDF]

, 2016
Activating mutations in MYD88 are present in approximately 95% of patients with Waldenstrom Macroglobulinemia (WM), as well as other B-cell malignancies including ABC DLBCL. In WM, mutated MYD88 triggers activation of BTK. Ibrutinib, a pleiotropic kinase
Advani, Bohers, Cao, Cao, Cheng, Chng, Christopher J. Patterson, Evans, Farré, Gay, Guang Yang, Gutiérrez, Hallek, Hanke, Hong, Honigberg, Janz, Jennifer R. Brown, Jiaji G. Chen, Jie Chen, Jorge J. Castillo, Jourdan, Juilland, Lam, Leleu, Li Tan, Lian Xu, Messeguer, Musumeci, Nathanael Gray, Ngo, Nicholas Tsakmaklis, O’Boyle, Patricelli, Pecquet, Pene-Dumitrescu, Philip Cohen, Poh, Sahota, Saito, Sanner, Sara J. Buhrlage, Schaeffer, Shuai Liu, Steven P. Treon, Suh, Taguchi, Treon, Treon, Treon, Trott, Varettoni, Wei Zhang, Wilson, Woyach, Xia Liu, Xiaofeng Zhang, Xu, Yang, Yang, Zachary R. Hunter   +60 more
core   +2 more sources

Treatment of Waldenstrom’s Macroglobulinemia

Current Treatment Options in Oncology, 2007
Waldenstrom's macroglobulinemia is defined by bone marrow lymphoplasmacytic infiltration and by production of monoclonal IgM. Treatment is employed only to symptomatic patients. Alkylating agents (chlorambucil), nucleoside analogues and rituximab are reasonable choices for primary therapy.
Dimopoulos, Meletios A, Anagnostopoulos, Athanasios   +1 more
openaire   +4 more sources

Waldenstrom macroglobulinemia involving the superior rectus muscle

American Journal of Ophthalmology Case Reports, 2018
Purpose: We present the first reported case of Waldenstrom macroglobulinemia in the right superior rectus causing diplopia. Observations: A 72-year-old man with a 6-month history of untreated asymptomatic Waldenstrom macroglobulinemia presented with 2 ...
J.B. Hellman, G.J. Harocopos, L.K. Lin
doaj   +1 more source

Candidate genes of Waldenström’s macroglobulinemia: current evidence and research [PDF]

, 2014
Waldenström’s macroglobulinemia (WM) is a relatively uncommon, indolent malignancy of immunoglobulin M-producing B cells. The World Health Organization classifies it as a lymphoplasmacytic lymphoma and patients typically present with anemia ...
Bianchi, Giada, Ghobrial, Irene, Kumar, Shaji, Roccaro, Aldo, Rossi, Giuseppe, Sacco, Antonio   +5 more
core   +1 more source

Bing-Neel syndrome, a rare complication of Waldenström macroglobulinemia: analysis of 44 cases and review of the literature. A study on behalf of the French Innovative Leukemia Organization (FILO).

Haematologica, 2015
Central nervous system involvement by malignant cells is a rare complication of Waldenström macroglobulinemia, and this clinicopathological entity is referred to as the Bing-Neel syndrome.
Laurence Simon, Aikaterini Fitsiori, Richard Lemal, Jehan Dupuis, Benjamin Carpentier, Laurys Boudin, Anne Corby, Thérèse Aurran-Schleinitz, Lauris Gastaud, Alexis Talbot, Stéphane Leprêtre, Béatrice Mahe, Camille Payet, Carole Soussain, Charlotte Bonnet, Laure Vincent, Séverine Lissandre, Raoul Herbrecht, Stéphane Kremer, Véronique Leblond, Luc-Matthieu Fornecker   +20 more
doaj   +1 more source

How to manage Waldenstrom’s macroglobulinemia [PDF]

Leukemia, 2013
Waldenstrom's macroglobulinemia (WM) is very distinct from other indolent lymphoma subtypes: by definition it is accompanied by a monoclonal IgM gammopathy; it presents always with bone marrow infiltration and often with clinical symptoms such as neuropathy or hyperviscosity.
Buske, C, Leblond, V
openaire   +2 more sources